health insurance plans covering glp-1 therapy 2025 GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Patients Face New Barriers for

Supplementary Movie 2

35 A meta-analysis of 29 U.S.-based lifestyle trials with professional intervention and at least two years of follow-up found that more than half of the lost weight was regained within two years

Compared to the control, T2DM patients treated with semaglutide 1 mg saw a reduction of 29 mg/dL (22%) for pre-prandial glucose, 74 mg/dL (36%) for 2-h postprandial glucose, and 30 mg/dL (22%) for mean 24-h glucose concentration [26]

Comparisons with liraglutide were exploratory and not adjusted for multiplicity

Abbott argued the case should be permanently closed, noting the plaintiffs legal team had known of the evidentiary gaps since 2022